カテゴリー： QYResearch, 世界, 医療/バイオ

認知障害治療のグローバル市場2023年：抗てんかん薬認知障害治療、抗精神病薬認知障害治療

◆英語タイトル：Global Cognitive Impairment Disorders Treatment Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA7445）◆商品コード：QYR23MA7445
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：109
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の認知障害治療市場について調査・分析し、世界の認知障害治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（抗てんかん薬認知障害治療、抗精神病薬認知障害治療）、用途別セグメント分析（病院薬局、専門クリニック、小売店、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Eli Lilly and Company、AstraZeneca、Bristol-Myers Squibb、Pfizer、Minerva Neurosciences、Intra-Cellular Therapies、Avineuro Pharmaceuticals、SyneuRx、Lundbeck、AB Science SA、AbbVie Inc、CHA Bio & Diostech Co Ltd、Echo Pharmaceuticals BV、Eisai Co Ltd、GlaxoSmithKline Plc、Grifols SA、Immungenetics AG、Otsuka Holdings Co Ltd、Merck & Co Inc、Kyowa Hakko Kirin Co Ltdなどが含まれています。世界の認知障害治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、認知障害治療市場規模を推定する際に考慮しました。

・認知障害治療市場の概要
- 認知障害治療のタイプ別セグメント
- 世界の認知障害治療市場規模：タイプ別分析（抗てんかん薬認知障害治療、抗精神病薬認知障害治療）
- 認知障害治療の用途別セグメント
- 世界の認知障害治療市場規模：用途別分析（病院薬局、専門クリニック、小売店、その他）
- 世界の認知障害治療市場規模予測（2018年-2029年）

・認知障害治療市場の成長トレンド
- 認知障害治療の地域別市場規模（2018年-2029年）
- 認知障害治療市場ダイナミクス
- 認知障害治療の業界動向
- 認知障害治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・タイプ別セグメント：抗てんかん薬認知障害治療、抗精神病薬認知障害治療
- 世界の認知障害治療のタイプ別市場規模（2018年-2023年）
- 世界の認知障害治療のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院薬局、専門クリニック、小売店、その他
- 世界の認知障害治療の用途別市場規模（2018年-2023年）
- 世界の認知障害治療の用途別市場規模（2024年-2029年）

・認知障害治療の地域別市場規模
- 北米の認知障害治療市場規模（2018年-2029年）
- アメリカの認知障害治療市場規模（2018年-2029年）
- ヨーロッパの認知障害治療市場規模（2018年-2029年）
- アジア太平洋の認知障害治療市場規模（2018年-2029年）
- 中国の認知障害治療市場規模（2018年-2029年）
- 日本の認知障害治療市場規模（2018年-2029年）
- 韓国の認知障害治療市場規模（2018年-2029年）
- インドの認知障害治療市場規模（2018年-2029年）
- オーストラリアの認知障害治療市場規模（2018年-2029年）
- 中南米の認知障害治療市場規模（2018年-2029年）
- 中東・アフリカの認知障害治療市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Eli Lilly and Company、AstraZeneca、Bristol-Myers Squibb、Pfizer、Minerva Neurosciences、Intra-Cellular Therapies、Avineuro Pharmaceuticals、SyneuRx、Lundbeck、AB Science SA、AbbVie Inc、CHA Bio & Diostech Co Ltd、Echo Pharmaceuticals BV、Eisai Co Ltd、GlaxoSmithKline Plc、Grifols SA、Immungenetics AG、Otsuka Holdings Co Ltd、Merck & Co Inc、Kyowa Hakko Kirin Co Ltd

・アナリストの観点/結論

・調査方法とデータソース

Highlights
The global Cognitive Impairment Disorders Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Cognitive Impairment Disorders Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cognitive Impairment Disorders Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Cognitive Impairment Disorders Treatment in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Cognitive Impairment Disorders Treatment include Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Minerva Neurosciences, Intra-Cellular Therapies, Avineuro Pharmaceuticals, SyneuRx and Lundbeck, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cognitive Impairment Disorders Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cognitive Impairment Disorders Treatment.
The Cognitive Impairment Disorders Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cognitive Impairment Disorders Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cognitive Impairment Disorders Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Pfizer
Minerva Neurosciences
Intra-Cellular Therapies
Avineuro Pharmaceuticals
SyneuRx
Lundbeck
AB Science SA
AbbVie Inc
CHA Bio & Diostech Co Ltd
Echo Pharmaceuticals BV
Eisai Co Ltd
GlaxoSmithKline Plc
Grifols SA
Immungenetics AG
Otsuka Holdings Co Ltd
Merck & Co Inc
Kyowa Hakko Kirin Co Ltd
Segment by Type
Antiepileptic Drugs Cognitive Impairment Disorders Treatment
Antipsychotics Drugs Cognitive Impairment Disorders Treatment
Segment by Application
Hospital Pharmacies
Specialty Clinics
Retail Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cognitive Impairment Disorders Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cognitive Impairment Disorders Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antiepileptic Drugs Cognitive Impairment Disorders Treatment
1.2.3 Antipsychotics Drugs Cognitive Impairment Disorders Treatment
1.3 Market by Application
1.3.1 Global Cognitive Impairment Disorders Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Specialty Clinics
1.3.4 Retail Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cognitive Impairment Disorders Treatment Market Perspective (2018-2029)
2.2 Cognitive Impairment Disorders Treatment Growth Trends by Region
2.2.1 Global Cognitive Impairment Disorders Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cognitive Impairment Disorders Treatment Historic Market Size by Region (2018-2023)
2.2.3 Cognitive Impairment Disorders Treatment Forecasted Market Size by Region (2024-2029)
2.3 Cognitive Impairment Disorders Treatment Market Dynamics
2.3.1 Cognitive Impairment Disorders Treatment Industry Trends
2.3.2 Cognitive Impairment Disorders Treatment Market Drivers
2.3.3 Cognitive Impairment Disorders Treatment Market Challenges
2.3.4 Cognitive Impairment Disorders Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cognitive Impairment Disorders Treatment Players by Revenue
3.1.1 Global Top Cognitive Impairment Disorders Treatment Players by Revenue (2018-2023)
3.1.2 Global Cognitive Impairment Disorders Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Cognitive Impairment Disorders Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cognitive Impairment Disorders Treatment Revenue
3.4 Global Cognitive Impairment Disorders Treatment Market Concentration Ratio
3.4.1 Global Cognitive Impairment Disorders Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cognitive Impairment Disorders Treatment Revenue in 2022
3.5 Cognitive Impairment Disorders Treatment Key Players Head office and Area Served
3.6 Key Players Cognitive Impairment Disorders Treatment Product Solution and Service
3.7 Date of Enter into Cognitive Impairment Disorders Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cognitive Impairment Disorders Treatment Breakdown Data by Type
4.1 Global Cognitive Impairment Disorders Treatment Historic Market Size by Type (2018-2023)
4.2 Global Cognitive Impairment Disorders Treatment Forecasted Market Size by Type (2024-2029)
5 Cognitive Impairment Disorders Treatment Breakdown Data by Application
5.1 Global Cognitive Impairment Disorders Treatment Historic Market Size by Application (2018-2023)
5.2 Global Cognitive Impairment Disorders Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cognitive Impairment Disorders Treatment Market Size (2018-2029)
6.2 North America Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cognitive Impairment Disorders Treatment Market Size by Country (2018-2023)
6.4 North America Cognitive Impairment Disorders Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cognitive Impairment Disorders Treatment Market Size (2018-2029)
7.2 Europe Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cognitive Impairment Disorders Treatment Market Size by Country (2018-2023)
7.4 Europe Cognitive Impairment Disorders Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cognitive Impairment Disorders Treatment Market Size (2018-2029)
8.2 Asia-Pacific Cognitive Impairment Disorders Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cognitive Impairment Disorders Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Cognitive Impairment Disorders Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cognitive Impairment Disorders Treatment Market Size (2018-2029)
9.2 Latin America Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cognitive Impairment Disorders Treatment Market Size by Country (2018-2023)
9.4 Latin America Cognitive Impairment Disorders Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cognitive Impairment Disorders Treatment Market Size (2018-2029)
10.2 Middle East & Africa Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cognitive Impairment Disorders Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Cognitive Impairment Disorders Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly and Company
11.1.1 Eli Lilly and Company Company Detail
11.1.2 Eli Lilly and Company Business Overview
11.1.3 Eli Lilly and Company Cognitive Impairment Disorders Treatment Introduction
11.1.4 Eli Lilly and Company Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.1.5 Eli Lilly and Company Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Cognitive Impairment Disorders Treatment Introduction
11.2.4 AstraZeneca Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.2.5 AstraZeneca Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Cognitive Impairment Disorders Treatment Introduction
11.3.4 Bristol-Myers Squibb Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Cognitive Impairment Disorders Treatment Introduction
11.4.4 Pfizer Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.4.5 Pfizer Recent Development
11.5 Minerva Neurosciences
11.5.1 Minerva Neurosciences Company Detail
11.5.2 Minerva Neurosciences Business Overview
11.5.3 Minerva Neurosciences Cognitive Impairment Disorders Treatment Introduction
11.5.4 Minerva Neurosciences Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.5.5 Minerva Neurosciences Recent Development
11.6 Intra-Cellular Therapies
11.6.1 Intra-Cellular Therapies Company Detail
11.6.2 Intra-Cellular Therapies Business Overview
11.6.3 Intra-Cellular Therapies Cognitive Impairment Disorders Treatment Introduction
11.6.4 Intra-Cellular Therapies Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.6.5 Intra-Cellular Therapies Recent Development
11.7 Avineuro Pharmaceuticals
11.7.1 Avineuro Pharmaceuticals Company Detail
11.7.2 Avineuro Pharmaceuticals Business Overview
11.7.3 Avineuro Pharmaceuticals Cognitive Impairment Disorders Treatment Introduction
11.7.4 Avineuro Pharmaceuticals Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.7.5 Avineuro Pharmaceuticals Recent Development
11.8 SyneuRx
11.8.1 SyneuRx Company Detail
11.8.2 SyneuRx Business Overview
11.8.3 SyneuRx Cognitive Impairment Disorders Treatment Introduction
11.8.4 SyneuRx Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.8.5 SyneuRx Recent Development
11.9 Lundbeck
11.9.1 Lundbeck Company Detail
11.9.2 Lundbeck Business Overview
11.9.3 Lundbeck Cognitive Impairment Disorders Treatment Introduction
11.9.4 Lundbeck Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.9.5 Lundbeck Recent Development
11.10 AB Science SA
11.10.1 AB Science SA Company Detail
11.10.2 AB Science SA Business Overview
11.10.3 AB Science SA Cognitive Impairment Disorders Treatment Introduction
11.10.4 AB Science SA Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.10.5 AB Science SA Recent Development
11.11 AbbVie Inc
11.11.1 AbbVie Inc Company Detail
11.11.2 AbbVie Inc Business Overview
11.11.3 AbbVie Inc Cognitive Impairment Disorders Treatment Introduction
11.11.4 AbbVie Inc Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.11.5 AbbVie Inc Recent Development
11.12 CHA Bio & Diostech Co Ltd
11.12.1 CHA Bio & Diostech Co Ltd Company Detail
11.12.2 CHA Bio & Diostech Co Ltd Business Overview
11.12.3 CHA Bio & Diostech Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.12.4 CHA Bio & Diostech Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.12.5 CHA Bio & Diostech Co Ltd Recent Development
11.13 Echo Pharmaceuticals BV
11.13.1 Echo Pharmaceuticals BV Company Detail
11.13.2 Echo Pharmaceuticals BV Business Overview
11.13.3 Echo Pharmaceuticals BV Cognitive Impairment Disorders Treatment Introduction
11.13.4 Echo Pharmaceuticals BV Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.13.5 Echo Pharmaceuticals BV Recent Development
11.14 Eisai Co Ltd
11.14.1 Eisai Co Ltd Company Detail
11.14.2 Eisai Co Ltd Business Overview
11.14.3 Eisai Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.14.4 Eisai Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.14.5 Eisai Co Ltd Recent Development
11.15 GlaxoSmithKline Plc
11.15.1 GlaxoSmithKline Plc Company Detail
11.15.2 GlaxoSmithKline Plc Business Overview
11.15.3 GlaxoSmithKline Plc Cognitive Impairment Disorders Treatment Introduction
11.15.4 GlaxoSmithKline Plc Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.15.5 GlaxoSmithKline Plc Recent Development
11.16 Grifols SA
11.16.1 Grifols SA Company Detail
11.16.2 Grifols SA Business Overview
11.16.3 Grifols SA Cognitive Impairment Disorders Treatment Introduction
11.16.4 Grifols SA Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.16.5 Grifols SA Recent Development
11.17 Immungenetics AG
11.17.1 Immungenetics AG Company Detail
11.17.2 Immungenetics AG Business Overview
11.17.3 Immungenetics AG Cognitive Impairment Disorders Treatment Introduction
11.17.4 Immungenetics AG Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.17.5 Immungenetics AG Recent Development
11.18 Otsuka Holdings Co Ltd
11.18.1 Otsuka Holdings Co Ltd Company Detail
11.18.2 Otsuka Holdings Co Ltd Business Overview
11.18.3 Otsuka Holdings Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.18.4 Otsuka Holdings Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.18.5 Otsuka Holdings Co Ltd Recent Development
11.19 Merck & Co Inc
11.19.1 Merck & Co Inc Company Detail
11.19.2 Merck & Co Inc Business Overview
11.19.3 Merck & Co Inc Cognitive Impairment Disorders Treatment Introduction
11.19.4 Merck & Co Inc Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.19.5 Merck & Co Inc Recent Development
11.20 Kyowa Hakko Kirin Co Ltd
11.20.1 Kyowa Hakko Kirin Co Ltd Company Detail
11.20.2 Kyowa Hakko Kirin Co Ltd Business Overview
11.20.3 Kyowa Hakko Kirin Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.20.4 Kyowa Hakko Kirin Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2018-2023)
11.20.5 Kyowa Hakko Kirin Co Ltd Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 認知障害治療のグローバル市場2023年：抗てんかん薬認知障害治療、抗精神病薬認知障害治療(Global Cognitive Impairment Disorders Treatment Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 血液腫瘍治療のグローバル市場2023年：化学療法、標的療法、免疫療法、その他
  • 腫瘍随伴性天疱瘡治療のグローバル市場2023年：皮下、静脈内、経口
  • フィラリア症治療のグローバル市場2023年：スプレー薬、服用薬、その他
  • コルチコステロイド反応性疾患のグローバル市場2023年：注射、経口
  • 潰瘍性大腸炎治療オプションのグローバル市場2023年：抗炎症薬、免疫抑制剤、その他医薬品